APOA1

Across TCGA pan-cancer cohorts, APOA1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated APOA1 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APOA1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated APOA1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where APOA1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.902	0.712	.002	36	view →
LUAD	OS	Median	III,IV	0.330	0.869	.006	23	view →
PDAC	OS	Median	All	0.788	0.904	.025	14	view →
OV	DFS	Median	All	0.938	0.615	.019	12	view →
HNSC	DFS	Tertile	III,IV	1.000	0.894	.021	9	view →
GBM	DFS	Median	All	0.514	0.257	.005	5	view →
UCEC	DFS	Tertile	III,IV	0.544	1.000	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

APOA1–CCRCC (DFS)

Open the CCRCC breakdown →